PharmaBoardroom today releases its new 70 page Switzerland Healthcare & Life Sciences Review 2016.
This report offers companies, investors, policymakers, and stakeholders crucial insight into Switzerland; a country located at the heart of Europe, home to some of the world’s most important international health institutions as well as two of its largest pharmaceutical companies in Novartis and Roche, and with a number one ranking globally in terms of ease of doing business and innovation. Switzerland is truly a healthcare and life sciences powerhouse.
The report features in-depth exclusive interviews with leading figures from public institutions and private companies, comprehensive articles, and up-to-date facts and figures on the Swiss healthcare and pharma sectors.
Featured topics include:
- Europe’s Brain: The growing number of MNCs choosing to their base global, EMEA or European headquarters in Switzerland
- Swiss Success Stories: The biotech and pharma start-ups gaining global recognition
- Inward Investment: A focus on Biogen’s billion dollar manufacturing plant
- Swiss Exceptionalism: As a non-member of the EU, how Switzerland’s healthcare system operates
- Regional Rivalries: The competing yet complementary Swiss pharma hotspots: Basel, Zurich, Zug and Geneva
The report features in-depth interviews with:
- Pascal Strupler, Federal Office of Public Health
- Walter Steinlin, Federal Commission of Technology and Innovation
- Dr. Oliver Bleck, Roche
- Walter P. Hölzle, vips
- Dr. Jean-Paul Clozel, Actelion
- Tuomo Pätsi, Celgene
- Prof. Jürg Utzinger, Swiss Tropical and Public Health Institute
- Jean-Daniel Gerber, SIFEM
- Kari Sarvanto, Primex
“[The Swiss healthcare] system works well and we have learned the importance of open communication and discussing differences”
Pascal Strupler, Federal Office of Public Health
“Switzerland represents an extremely fertile ground for scientific findings… we boast some of the very best researchers in the world”
Walter Steinlin, CTI
“It’s certainly true that Switzerland is an expensive place to operate, but it is other factors, aside from wage prices that validate our decision to conduct the manufacturingfrom here in Schaffhausen.”
Ludo Ooms, Janssen
“When you ask a CEO how relevant the high local operating costs are to their eventual investment decision-making, the reply is almost always that they assign more attention to the level of productivity.”
Thomas Cueni, Interpharma
Click here to download the report.